APA (7th ed.) Citation

Maceski, A. M., Benkert, P., Einsiedler, M., Schaedelin, S., Oechtering, J., Melie-Garcia, L., . . . Müller, J. (2026). GFAP and NfL as predictors of disease progression and relapse activity in fingolimod-treated multiple sclerosis. Brain: A Journal of Neurology, 149(7), 2295. https://doi.org/10.1093/brain/awaf433

Chicago Style (17th ed.) Citation

Maceski, Aleksandra Maleska, et al. "GFAP and NfL as Predictors of Disease Progression and Relapse Activity in Fingolimod-treated Multiple Sclerosis." Brain: A Journal of Neurology 149, no. 7 (2026): 2295. https://doi.org/10.1093/brain/awaf433.

MLA (9th ed.) Citation

Maceski, Aleksandra Maleska, et al. "GFAP and NfL as Predictors of Disease Progression and Relapse Activity in Fingolimod-treated Multiple Sclerosis." Brain: A Journal of Neurology, vol. 149, no. 7, 2026, p. 2295, https://doi.org/10.1093/brain/awaf433.